...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Haematology >New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients
【24h】

New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients

机译：使用基因表达分析确定的新的预后指标，揭示了慢性粒细胞性白血病患者的两种不同亚型

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chronic myelomonocytic leukaemia (CMML) is a heterogeneous haematopoietic disorder characterized by myeloproliferative or myelodysplastic features. At present, the pathogenesis of this malignancy is not completely understood. In this study, we sought to analyse gene expression profiles of CMML in order to characterize new molecular outcome predictors. A learning set of 32 untreated CMML patients at diagnosis was available for TaqMan low-density array gene expression analysis. From 93 selected genes related to cancer and cell cycle, we built a five-gene prognostic index after multiplicity correction. Using this index, we characterized two categories of patients with distinct overall survival (94% vs. 19% for good and poor overall survival, respectively; P = 0·007) and we successfully validated its strength on an independent cohort of 21 CMML patients with Affymetrix gene expression data. We found no specific patterns of association with traditional prognostic stratification parameters in the learning cohort. However, the poor survival group strongly correlated with high-risk treated patients and transformation to acute myeloid leukaemia. We report here a new multigene prognostic index for CMML, independent of the gene expression measurement method, which could be used as a powerful tool to predict clinical outcome and help physicians to evaluate criteria for treatments.
机译：慢性粒细胞单核细胞白血病（CMML）是一种异质性造血疾病，其特征在于骨髓增生或骨髓增生异常。目前，尚未完全了解这种恶性肿瘤的发病机理。在这项研究中，我们试图分析CMML的基因表达谱，以表征新的分子结果预测因子。 TaqMan低密度阵列基因表达分析提供了32个未经诊断的CMML诊断患者的学习集。从93个与癌症和细胞周期相关的基因中，我们通过多重校正建立了一个五基因的预后指标。使用该指数，我们对两类具有不同总体生存率的患者进行了分类（总体生存率好和差的分别为94％和19％; P = 0·007），我们通过独立队列的21名CMML患者成功地验证了其强度Affymetrix基因表达数据。我们在学习队列中未发现与传统预后分层参数相关的特定模式。但是，生存期较差的人群与接受高风险治疗的患者以及向急性骨髓性白血病的转化高度相关。我们在这里报告了一种新的CMML多基因预后指数，与基因表达测量方法无关，它可以用作预测临床结果并帮助医生评估治疗标准的有力工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号